The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
We describe the response of imatinib as lifesaving treatment of chronic myeloid leukemia (CML) relapse in seven patients who underwent allogeneic bone marrow transplantation (alloBMT) at our institution ov...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2009/357093 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551548753805312 |
|---|---|
| author | Monika Conchon Sabri S. Sanabani Israel Bendit Carla Luana Dinardo Lucia Dias Dalton de Alencar Fischer Chamone Pedro Enrique Dorlhiac-Llacer Frederico Luiz Dulley |
| author_facet | Monika Conchon Sabri S. Sanabani Israel Bendit Carla Luana Dinardo Lucia Dias Dalton de Alencar Fischer Chamone Pedro Enrique Dorlhiac-Llacer Frederico Luiz Dulley |
| author_sort | Monika Conchon |
| collection | DOAJ |
| description | We describe the
response of imatinib as lifesaving treatment of
chronic myeloid leukemia (CML) relapse in seven
patients who underwent allogeneic bone marrow
transplantation (alloBMT) at our institution
over a period of 4 years. Retrospective analysis
of their medical records revealed that a mean age at
transplant was 45.2 years. The median time to
diagnosis was 7.4 years after transplant. At
relapse, four, two, and one patients were
classified as having hematologic, major
molecular, and cytogenetic relapse, respectively.
At imatinib initiation, five had CML in a
chronic phase, while one patient was
diagnosed as having accelerated phase and blast
crisis. All these patients could be evaluated
for the therapeutic efficacy. At a mean of
follow-up of 1.9 years of therapy, all evaluable
patients achieved major molecular response
without compromising safety. Consistent with
available data, our results indicate that
imatinib is safe and effective treatment option
for patients with relapse after
BMT. |
| format | Article |
| id | doaj-art-801aa3bedf904ee09c6146c40d51fe23 |
| institution | Kabale University |
| issn | 2090-0007 2090-0015 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Transplantation |
| spelling | doaj-art-801aa3bedf904ee09c6146c40d51fe232025-02-03T06:01:14ZengWileyJournal of Transplantation2090-00072090-00152009-01-01200910.1155/2009/357093357093The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow TransplantationMonika Conchon0Sabri S. Sanabani1Israel Bendit2Carla Luana Dinardo3Lucia Dias4Dalton de Alencar Fischer Chamone5Pedro Enrique Dorlhiac-Llacer6Frederico Luiz Dulley7Disciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, BrazilFundação Pro-Sangue/ Hemocentro de São Paulo, 05403-000 São Paulo, BrazilDisciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, BrazilDisciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, BrazilDisciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, BrazilDisciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, BrazilDisciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, BrazilDisciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, BrazilWe describe the response of imatinib as lifesaving treatment of chronic myeloid leukemia (CML) relapse in seven patients who underwent allogeneic bone marrow transplantation (alloBMT) at our institution over a period of 4 years. Retrospective analysis of their medical records revealed that a mean age at transplant was 45.2 years. The median time to diagnosis was 7.4 years after transplant. At relapse, four, two, and one patients were classified as having hematologic, major molecular, and cytogenetic relapse, respectively. At imatinib initiation, five had CML in a chronic phase, while one patient was diagnosed as having accelerated phase and blast crisis. All these patients could be evaluated for the therapeutic efficacy. At a mean of follow-up of 1.9 years of therapy, all evaluable patients achieved major molecular response without compromising safety. Consistent with available data, our results indicate that imatinib is safe and effective treatment option for patients with relapse after BMT.http://dx.doi.org/10.1155/2009/357093 |
| spellingShingle | Monika Conchon Sabri S. Sanabani Israel Bendit Carla Luana Dinardo Lucia Dias Dalton de Alencar Fischer Chamone Pedro Enrique Dorlhiac-Llacer Frederico Luiz Dulley The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation Journal of Transplantation |
| title | The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation |
| title_full | The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation |
| title_fullStr | The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation |
| title_full_unstemmed | The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation |
| title_short | The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation |
| title_sort | use of imatinib mesylate as a lifesaving treatment of chronic myeloid leukemia relapse after bone marrow transplantation |
| url | http://dx.doi.org/10.1155/2009/357093 |
| work_keys_str_mv | AT monikaconchon theuseofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT sabrissanabani theuseofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT israelbendit theuseofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT carlaluanadinardo theuseofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT luciadias theuseofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT daltondealencarfischerchamone theuseofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT pedroenriquedorlhiacllacer theuseofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT fredericoluizdulley theuseofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT monikaconchon useofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT sabrissanabani useofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT israelbendit useofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT carlaluanadinardo useofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT luciadias useofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT daltondealencarfischerchamone useofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT pedroenriquedorlhiacllacer useofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation AT fredericoluizdulley useofimatinibmesylateasalifesavingtreatmentofchronicmyeloidleukemiarelapseafterbonemarrowtransplantation |